Table 4 Comparison of adverse events between Endostar combined with chemotherapeutic agents versus chemotherapeutic agents alone
Study | Myelotoxicity (%) | Nausea/vomiting (%) | Liver and renal injury (%) | Arrhythmia (%) | Fever (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | |
Li G 2011 [17] | 4 (13.3) | 4 (13.3) | 4 (13.3) | 3 (10) | – | – | 1 (3.3) | 0 (0) | 7 (23.3) | 6 (20) |
Yao Q 2012 [19] | 12 (40) | 10 (30) | 5 (16.7) | 5 (16.7) | – | – | – | – | – | – |
Zheng Q 2013 [20] | 17 (28.3) | 16 (26.6) | 10 (16.7) | 5 (8.3) | – | – | – | – | – | – |
Kang Y 2013 [21] | 11 (24.4) | 10 (22.2) | 15 (25) | 15 (25) | 4 (8.8) | 3 (6.6) | 2 (3.3) | 0 (0) | 7 (15.5) | 5 (11.1) |
Wen J 2014 [22] | 22 (73.3) | 20 (66.6) | 6 (20) | 4 (13.3) | – | – | 5 (16.6) | 1 (3.3) | – | – |
Yue G 2014 [23] | 10 (23.3) | 8 (18.6) | 7 (16.3) | 6 (14) | – | – | – | – | – | – |
Tu J 2014 [24] | 7 (15.5) | 9 (20) | 9 (20) | 9 (20) | 2 (4.4) | 2 (4.4) | 2 (4.4) | 1 (2.2) | – | – |
Xu J 2014 [25] | 14 (40) | 9 (25.7) | 4 (11.4) | 2 (5.7) | 2 (5.7) | 1 (2.8) | 1 (2.8) | 1 (2.8) | 1 (2.8) | 0 (0) |
Hu X 2015 [27] | 7 (16.3) | 5 (12.2) | 26 (60.4) | 20 (48.7) | 5 (11.6) | 5 (12.1) | 3 (6.9) | 3 (7.3) | 5 (11.6) | 5 (12.1) |
P > 0.05 | P > 0.05 | P > 0.05 | P > 0.05 | P > 0.05 | ||||||